Bjørn-Eivind Kirsebom
Job description
Forskning, undervisning og veiledning innen klinisk nevropsykologi/nevrologi med spesielt fokus på demenssykdomer.
Leder Dementia Disease Initiation (DDI) avd. Tromsø.
Therese Händel Waggestad,
Bjørn-Eivind Seljelid Kirsebom,
Carsten Strobel,
Linda Gjøra,
Geir Selbæk,
Peter Wetterberg
et al.:
New regression-based norms for the Trail Making Test on Norwegian older adults: Understanding the effect of education
The Clinical Neuropsychologist 2025 DOI
Anders Wimo,
Ron Handels,
Kaj Blennow,
Bjørn-Eivind Kirsebom,
Per Selnes,
Jaka Bon
et al.:
Cost-effectiveness of diagnosing and treating patients with early Alzheimer's disease with anti-amyloid treatment in a clinical setting
Journal of Alzheimer's Disease 2025 DOI
Fernando Gonzalez-Ortiz,
Bjørn-Eivind Kirsebom,
Yara Yakoub,
Julia Kristine Gundersen,
Lene Pålhaugen,
Knut Waterloo
et al.:
Associations Between Changes in Levels of Phosphorylated Tau and Severity of Cognitive Impairment in Early Alzheimer Disease
Neurology 2025 DOI
Ingrid Myrvoll Lorentzen,
Johan Jacob Espenes,
Ingvild Vøllo Eliassen,
Erik Hessen,
Knut Waterloo,
Santiago Timón-Reina
et al.:
Norwegian normative data for regression-based D-KEFS color-word interference test derived measures and comparison to conventional contrast measures
Applied neuropsychology: Adult 2025 DOI
Stephanie Knudtzon,
Kaja Nordengen,
Lene Pålhaugen,
Berglind Gísladóttir,
Jonas Alexander Jarholm,
Geir Bråthen
et al.:
Sexual dimorphisms in innate immune activation markers in predementia Alzheimer’s disease
Brain Communications 2025 DOI
Wietse A. Wiels,
Julie E. Oomens,
Sebastiaan Engelborghs,
Chris Baeken,
Christine A.F. Von Arnim,
Mercè Boada
et al.:
Depressive Symptoms and Amyloid Pathology
JAMA psychiatry 2025 DOI
Bjørn-Eivind Kirsebom,
Fernando Gonzalez-Ortiz,
Sinthujah Vigneswaran,
Geir Bråthen,
Ragnhild Eide Skogseth,
Berglind Gísladóttir
et al.:
Repeated plasma p-tau217 measurements to monitor clinical progression heterogeneity
Alzheimer's & Dementia 2025 DOI
Mathilde Suhr Hemminghyth,
Monica Haraldseid Breitve,
Luiza Chwiszczuk,
Berglind Gísladóttir,
Erik Hessen,
Nikias Ioannis Siafarikas
et al.:
Demographically unadjusted cognitive test scores may enhance the validity of mild cognitive impairment as a dementia prodrome
Applied neuropsychology: Adult 2025 DOI
Robin Ziyue Zhou,
Stefan Gaunitz,
Bjørn-Eivind Kirsebom,
Britt Lundin,
Marie Hellström,
Alenka Jejcic
et al.:
Blood N-glycomics reveals individuals at risk for cognitive decline and Alzheimer's disease
EBioMedicine 2025 DOI
Mostafa Mehdipour Ghazi,
Per Selnes,
Santiago Timon Reina,
Sandra Raquel Ramos Teceläo,
Silvia Ingala,
Atle Bjørnerud
et al.:
Comparative analysis of multimodal biomarkers for amyloid-beta positivity detection in Alzheimer's disease cohorts
Julia Kristine Gundersen,
Fernando Gonzalez-Ortiz,
Thomas Karikari,
Bjørn-Eivind Seljelid Kirsebom,
Katrin Mertes,
Henrik Zetterberg
et al.:
Neuronal plasma biomarkers in acute ischemic stroke
Anders Wimo,
Bjørn-Eivind Seljelid Kirsebom,
Santiago Timon Reina,
Ellen Vromen,
Per Selnes,
Jaka Bon
et al.:
Costs of diagnosing early Alzheimer's disease in three European memory clinic settings: Results from the precision medicine in Alzheimer's disease project
Cecilia Magdalena Eriksson,
Bjørn-Eivind Seljelid Kirsebom,
Ragna Espenes,
Nikias Ioannis Siafarikas,
Knut Waterloo,
Arvid Rongve
et al.:
Depressive Symptoms Are Not Associated with Predementia Cerebrospinal Fluid Amyloid Pathology
Sofia Egebäck Arulf,
Robin Ziyue Zhou,
Bjørn-Eivind Seljelid Kirsebom,
Alenka Jejcic,
Tormod Fladby,
Bengt Winblad
et al.:
Bisecting N-Acetylglucosamine Correlates with Phospho-Tau181 in Subjective Cognitive Decline but not in Control Cases
Journal of Alzheimer's Disease 2024 DOI
Fernando Gonzalez-Ortiz,
Thomas K. Karikari,
Danielle Taylor-Te Vruchte,
Dawn Shepherd,
Bjørn-Eivind Seljelid Kirsebom,
Tormod Fladby
et al.:
Plasma phosphorylated-tau217 is increased in Niemann–Pick disease type C
Fernando Gonzalez-Ortiz,
Bjørn-Eivind Seljelid Kirsebom,
José Contador,
Jordan E. Tanley,
Per Selnes,
Berglind Gisladottir
et al.:
Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer’s disease
Stephanie Knudtzon,
Kaja Nordengen,
Gøril Rolfseng Grøntvedt,
Jonas Alexander Jarholm,
Ingvild Vøllo Eliassen,
Per Selnes
et al.:
Age-adjusted CSF t-tau and NfL do not improve diagnostic accuracy for prodromal Alzheimer’s Disease
Giuseppe Mario Bentivenga,
Fernando Gonzalez-Ortiz,
Simone Baiardi,
Bjørn-Eivind Seljelid Kirsebom,
Andrea Mastrangelo,
Angela Mammana
et al.:
Clinical value of novel blood-based tau biomarkers in Creutzfeldt–Jakob disease
Kaja Nordengen,
Bjørn-Eivind Seljelid Kirsebom,
Grit Richter,
Lene Pålhaugen,
Berglind Gisladottir,
Nikias Ioannis Siafarikas
et al.:
Longitudinal cerebrospinal fluid measurements show glial hypo- and hyperactivation in predementia Alzheimer’s disease
Fredrik Öhman,
Marie Eckerström,
Erik Hessen,
Johan Jacob Espenes,
Ingvild Vøllo Eliassen,
Ingrid Myrvoll Lorentzen
et al.:
Demographically adjusted Rey–Osterrieth Complex Figure Test norms in a Swedish and Norwegian cohort aged 49–77 years and comparison with North American norms
Mathilde Suhr Hemminghyth,
Luiza Chwiszczuk,
Monica Haraldseid Breitve,
Berglind Gisladottir,
Gøril Rolfseng Grøntvedt,
Arne Exner Nakling
et al.:
Cerebrospinal fluid neurofilament light chain mediates age-associated lower learning and memory in healthy adults
Johan Jacob Espenes,
Ingrid Myrvoll Lorentzen,
Ingvild Vøllo Eliassen,
Erik Hessen,
Knut K Waterloo,
Santiago Timón
et al.:
Regression-based normative data for the D-KEFS Color-Word Interference Test in Norwegian adults ages 20–85
Therese Händel Waggestad,
Bjørn-Eivind Kirsebom,
Carsten Strobel,
Anders Wallin,
Marie Eckerström,
Tormod Fladby
et al.:
Improving validity of the trail making test with alphabet support
Jonas Alexander Jarholm,
Atle Bjørnerud,
Turi Olene Dalaker,
Mehdi Sadat Akhavi,
Bjørn-Eivind Kirsebom,
Lene Pålhaugen
et al.:
Medial Temporal Lobe Atrophy in Predementia Alzheimer's Disease: A Longitudinal Multi-Site Study Comparing Staging and A/T/N in a Clinical Research Cohort
Ingrid Myrvoll Lorentzen,
Johan Jacob Espenes,
Ingvild Vøllo Eliassen,
Erik Hessen,
Knut K Waterloo,
Arne Exner Nakling
et al.:
Investigating the relationship between allocentric spatial working memory and biomarker status in preclinical and prodromal Alzheimer’s disease
Klaus Thanke Aspli,
Jan Aaseth,
Trygve Holmøy,
Kaj Blennow,
Henrik Zetterberg,
Bjørn-Eivind Seljelid Kirsebom
et al.:
CSF, Blood, and MRI Biomarkers in Skogholt’s Disease—A Rare Neurodegenerative Disease in a Norwegian Kindred
Santiago Timón,
Mariano Rincón,
Rafael Martínez-Tomás,
Bjørn-Eivind Seljelid Kirsebom,
Tormod Fladby
:
A Knowledge Graph Framework for Dementia Research Data
Bjørn-Eivind Kirsebom,
Grit Richter,
Kaja Nordengen,
Dag Aarsland,
Geir Bråthen,
Betty M Tijms
et al.:
Stable cerebrospinal fluid neurogranin and β-site amyloid precursor protein cleaving enzyme 1 levels differentiate predementia Alzheimer's disease patients
Ingvild Vøllo Eliassen,
Bjørn-Eivind Kirsebom,
Tormod Fladby,
Knut Waterloo,
Sigrid Botne Sando,
Mathilde Suhr Hemminghyth
et al.:
Regression-Based Cognitive Change Norms Applied in Biochemically Defined Predementia Alzheimer’s Disease
Jacob Espenes,
Ingvild Vøllo Eliassen,
Fredrik Öhman,
Erik Hessen,
Knut K Waterloo,
Marie Eckerström
et al.:
Regression‐based normative data for the Rey Auditory Verbal Learning Test in Norwegian and Swedish adults aged 49–79 and comparison with published norms
Miguel Germán Borda,
Daniel Ferreira,
Per Selnes,
Diego Alejandro Tovar-Rios,
Alberto Jaramillo-Jiménez,
Bjørn-Eivind Kirsebom
et al.:
Timed Up and Go in People with Subjective Cognitive Decline Is Associated with Faster Cognitive Deterioration and Cortical Thickness
Ingrid Myrvoll Lorentzen,
Johan Jacob Espenes,
Erik Hessen,
Knut Waterloo,
Geir Bråthen,
Santiago Timón
et al.:
Regression-based norms for the FAS phonemic fluency test for ages 40–84 based on a Norwegian sample
Nikias Ioannis Siafarikas,
Bjørn-Eivind Kirsebom,
Deepak P Srivastava,
Cecilia Magdalena Eriksson,
Eirik Auning,
Erik Hessen
et al.:
Cerebrospinal fluid markers for synaptic function and Alzheimer type changes in late life depression
Johan Jacob Espenes,
Erik Hessen,
Ingvild Vøllo Eliassen,
Knut Waterloo,
Marie Eckerström,
Sigrid Botne Sando
et al.:
Demographically adjusted trail making test norms in a Scandinavian sample from 41 to 84 years
Ingvild Vøllo Eliassen,
Tormod Fladby,
Bjørn-Eivind Kirsebom,
Knut Waterloo,
Marie Eckerström,
Anders Wallin
et al.:
Predictive and diagnostic utility of brief neuropsychological assessment in detecting Alzheimer's pathology and progression to dementia
Anne Katrine Bergland,
Petroula Proitsi,
Bjørn-Eivind Kirsebom,
Hogne Sønnesyn,
Abdul Hye,
Alf Inge Larsen
et al.:
Exploration of plasma lipids in mild cognitive impairment due to Alzheimer's disease
Journal of Alzheimer's Disease 2020 DOI
Ragna Espenes,
Bjørn-Eivind Kirsebom,
Cecilia Magdalena Eriksson,
Knut K Waterloo,
Erik Hessen,
Stein Harald Johnsen
et al.:
Amyloid plaques and symptoms of depression links to medical help-seeking due to subjective cognitive decline
Erik Hessen,
Bjørn-Eivind Kirsebom,
Cecilia Magdalena Eriksson,
Carl Fredrik Andestad Eliassen,
Arne Nakling,
Geir Bråthen
et al.:
In Brief Neuropsychological Assessment, Amnestic Mild Cognitive Impairment (MCI) Is associated with Cerebrospinal Fluid Biomarkers for Cognitive Decline in Contrast to the Prevailing NIA-AA MCI Criterion
Bjørn-Eivind Kirsebom,
Ragna Espenes,
Erik Hessen,
Knut Waterloo,
Stein Harald Johnsen,
Elisabeth Gundersen
et al.:
Demographically adjusted CERAD wordlist test norms in a Norwegian sample from 40 to 80 years
Mathilde Suhr Hemminghyth,
Monica Haraldseid Breitve,
Berglind Gisladottir,
Gøril Rolfseng Grøntvedt,
Arne Exner Nakling,
Tormod Fladby
et al.:
Cerebrospinal fluid neurofilament light chain mediates age-related decline in learning and memory in healthy adults
2023
Luiza Chwiszczuk,
Monica Haraldseid Breitve,
Bjørn-Eivind Kirsebom,
Per Selnes,
John Christian Jøraholmen Fløvig,
Anne Brita Knapskog
et al.:
The ANeED study – ambroxol in new and early dementia with Lewy bodies (DLB): protocol for a phase IIa multicentre, randomised, double-blinded and placebo-controlled trial
Nikias Ioannis Siafarikas,
Bjørn-Eivind Kirsebom,
Deepak P. Srivastava,
Cecilia Magdalena Eriksson,
Eirik Auning,
Erik Hessen
et al.:
Author Correction: Cerebrospinal fluid markers for synaptic function and Alzheimer type changes in late life depression (Scientific Reports, (2021), 11, 1, (20375), 10.1038/s41598-021-99794-9)
Scientific Reports 2022 DOI
Johan Jacob Espenes,
Ingvild Vøllo Eliassen,
Tormod Fladby,
Marie Eckerström,
Wallin Anders,
Knut Waterloo
et al.:
Demographically adjusted test norms for the Rey Auditory Verbal Learning Test in Norwegian and Swedish adults
from 41 to 79 years
2020
Bjørn-Eivind Kirsebom
:
Hva vet vi om Alzheimers sykdom i dag, og finnes det en kur?
21. September 2020
Bjørn-Eivind Kirsebom
:
Tromsø-forskere jobber intenst med å løse alzheimer-gåten
28. Dezember 2019
Johan Jacob Espenes,
Bjørn-Eivind Kirsebom,
Ingvild Eliassen Vøllo,
Ragna Espenes,
Knut Waterloo,
Erik Hessen
et al.:
Demographically adjusted norms for basic and derived measures on the Trail Making Test A & B based on a Norwegian sample age 40 – 84 years.
2019
Bjørn-Eivind Kirsebom,
Tine Viktoria Buberg
:
Forsker på demens: – Antioksidanter fra blåbær kan bidra til å bremse demens
07. August 2019
Bjørn-Eivind Kirsebom
:
Frykter fordobling av demenstilfeller innen 2050: Tromsø-forskere undersøker om blåbær kan være kuren
14. August 2019
Bjørn-Eivind Kirsebom
:
Vil avdekke Alzheimers sykdom så tidlig som mulig
05. Juni 2019
Bjørn-Eivind Kirsebom,
Per Selnes,
Grit Richter,
Berglind Gisladottir,
Marianne Wettergreen,
Silje Bøen Torsetnes
et al.:
Cerebrospinal fluid Neurogranin/BACE1 ratio differentiate normal controls, pre-dementia Alzheimer’s and Parkinson’s disease cases.
2019
The 50 latest publications is shown on this page. See all publications in Cristin here →
Research interests
Klinisk nevropsykologi og regresjonsbaserte normer. Preklinisk og prodromal Alzheimers sykdom.